DATA SHEET

Eviti® Evidence-Based Medicine Library and Clinical Trials Database

Eviti empowers oncology professionals to make informed treatment decisions with the most comprehensive oncology clinical library available, ensuring that high-quality, high-value care is prescribed for all patients.

EVIDENCE-BASED MEDICINE LIBRARY FACTS

- Over 5,000 peer-reviewed, evidence-based, multi-modality oncology regimens encoded in proprietary format to facilitate quality care and its reimbursement at the moment of clinical prescribing
- Over 10,000 federally-registered cancer clinical trials through data feeds from the National Cancer Institute
- Managed within the NantHealth proprietary content management system by a team of oncology and informatics professionals
- Clinical content is developed through comprehensive study and surveillance of the accepted standards of practice, national oncology consensus group practice guidelines, and published clinical trials.

REGIMENS IN THE EVIDENCE-BASED MEDICINE LIBRARY ARE SUPPORTED BY:

- US Food and Drug Administration [FDA]
- National Cancer Institute [NCI]
- American Society for Therapeutic Radiology and Oncology [ASTRO]
- National Comprehensive Cancer Network [NCCN] Compendium
- American College of Radiology [ACR]
- American Society of Clinical Oncology [ASCO]
- Other recognized medical societies

The Eviti platform facilitates informed decision making by providing access to valuable details for each regimen, including level of evidence, expected outcomes, top five toxicities, literature references and cost information. Eviti also enables the setting of practice and/or payer preferred treatment options to promote value-based oncology care.

Minimum Requirements for Inclusion in the Library:



1. The treatment must be recommended by one of the nationality/ internationally recognized oncology consensus group organizations.
2. Data from the supporting clinical trial must be available. For recommendation or endorsed treatments that do not have diagnosis-specific clinical trial support, data may be extrapolated from closely-related clinical studies.
3. Each individual drug within the regimen must be FDA approved for marketing in the US, meaning the drugs are not experimental.

URAC ACCREDITED
Health Utilization Management 09/01/2025

r2 RISK-BASED 2-YEAR HITRUST CERTIFIED

ACCREDITED NCQA UTILIZATION MANAGEMENT

For more information, visit us online at NantHealth.com or email PayerSales@NantHealth.com.